Skip to main content
Erschienen in: Trials 1/2019

Open Access 01.12.2019 | Correction

Correction to: Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial

verfasst von: Thomas G. de Leeuw, Laura Mangiarini, Rebecca Lundin, Florentia Kaguelidou, Tjitske van der Zanden, Oscar Della Pasqua, Dick Tibboel, Adriana Ceci, Saskia N. de Wildt, on behalf of the GAPP consortium

Erschienen in: Trials | Ausgabe 1/2019

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1186/​s13063-018-3169-3
Correction to: Trials (2019) 20:49.
https://doi.org/10.1186/s13063-018-3169-3
Following publication of the original article [1], we have been notified that the tagging of one of the author names was done incorrectly in the XML version of the paper. Original and corrected tagging can be seen below.
  • Incorrect name tagging:
    Last Name: Pasqua.
    First Name: Oscar Della.
  • Correct author name tagging:
    Last Name: Della Pasqua.
    First Name: Oscar.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Correction to: Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial
verfasst von
Thomas G. de Leeuw
Laura Mangiarini
Rebecca Lundin
Florentia Kaguelidou
Tjitske van der Zanden
Oscar Della Pasqua
Dick Tibboel
Adriana Ceci
Saskia N. de Wildt
on behalf of the GAPP consortium
Publikationsdatum
01.12.2019
Verlag
BioMed Central
Erschienen in
Trials / Ausgabe 1/2019
Elektronische ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-019-3519-9

Weitere Artikel der Ausgabe 1/2019

Trials 1/2019 Zur Ausgabe